Skip to content

US · AIMDW · BIOTECHNOLOGY

Ainos, Inc. (AIMDW) intrinsic value and stock valuation

$0.03as of 2026-11-21 · Mkt cap 5.93M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Ainos, Inc. DCF and intrinsic value

InvestorsCraft values AIMDW with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from AIMDW’s statements →

Ainos, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Houston, TX 77056 ainos.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$120K+43.1% 5y CAGRd
20112025
Net income
-$-14.77M
20112025
Free cash flow
-$-4.65M
20112025
Total equity
$7.56M
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$120K$20K$120K$3.52M$590K
Operating income-$-13.99M-$-13.84M-$-13.21M-$-13.98M-$-3.87M
Net income-$-14.77M-$-14.86M-$-13.77M-$-14.01M-$-3.89M
EPSd-$-3.46M-$-1.56M-$-3.36M-$-5.13M-$-2.58M
Operating cash flow-$-4.61M-$-5.81M-$-4.69M-$-3.04M-$-1.25M
Capital expenditure-$-30K-$-20K-$-90K-$-630K-$-140K
Free cash flow-$-4.65M-$-5.83M-$-4.79M-$-3.67M-$-1.39M
Total assets$20.9M$28.8M$31.8M$37.1M$40.8M
Total debt$11M$12M$5.96M$1.27M$3.62M
Net debt$10.6M$8.11M$4.08M-$-580K$1.87M
Total equity$7.56M$15.5M$24.5M$34.6M$10.2M
Cash and short-term investments$420K$3.89M$1.89M$1.85M$1.75M
Income statement
20252024202320222021
Revenue$120K$20K$120K$3.52M$590K
Cost of revenue$4.8M$50K$380K$2.11M$180K
Gross profit-$-4.68M-$-30K-$-250K$1.41M$410K
Research and development expenses$7.75M$8.41M$7.32M$6.85M$1.92M
Selling, general and administrative expenses$1.56M$5.4M$5.64M$8.54M$2.36M
Other expenses$0.00$0.00$0.00$0.00$0.00
Operating expenses$9.31M$13.8M$13M$15.4M$4.28M
Cost and expenses$14.1M$13.9M$13.3M$17.5M$4.46M
Interest income$0.00$0.00$0.00$0.00$0.00
Interest expense$710K$620K$140K$50K$20K
Depreciation and amortization$4.78M$4.8M$4.87M$4.81M$2.04M
Ebitda-$-9.28M-$-9.44M-$-8.77M-$-9.14M-$-1.83M
Operating income-$-13.99M-$-13.84M-$-13.21M-$-13.98M-$-3.87M
Total other income/expenses, net-$-780K-$-1.02M-$-560K-$-30K-$-10K
Income before tax-$-14.77M-$-14.86M-$-13.77M-$-14.01M-$-3.87M
Income tax expense$0.00$0.00$0.00$0.00$20K
Net income-$-14.77M-$-14.86M-$-13.77M-$-14.01M-$-3.89M
Weighted average shares outstanding$4.27M$9.5M$4.1M$2.73M$1.51M
Weighted average diluted shares outstanding$4.27M$9.5M$4.1M$2.73M$1.51M
Balance sheet
20252024202320222021
Cash and short-term investments$420K$3.89M$1.89M$1.85M$1.75M
Net receivables$0.00$0.00$0.00$200K$0.00
Inventory$300K$140K$170K$600K$0.00
Total current assets$1.14M$4.34M$2.47M$2.85M$2.22M
Property, plant and equipment, net$340K$560K$880K$1.38M$1.19M
Goodwill and intangible assets$19.2M$23.8M$28.3M$32.8M$37.3M
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$19.7M$24.5M$29.4M$34.3M$38.6M
Total assets$20.9M$28.8M$31.8M$37.1M$40.8M
Accounts payable$0.00$0.00$0.00$0.00$0.00
Short-term debt$0.00$3M$40K$1.26M$3.59M
Deferred revenue$350K$110K$110K$0.00$0.00
Total current liabilities$1.08M$3.95M$1.34M$2.47M$30.6M
Long-term debt$11M$9M$5.92M$10K$30K
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$12.2M$9.35M$6.06M$10K$30K
Capital lease obligations$0.00$0.00$0.00$10K$30K
Total liabilities$13.3M$13.3M$7.39M$2.48M$30.6M
Common stock$70K$150K$50K$40K$100K
Retained earnings-$-67.52M-$-52.75M-$-37.89M-$-24.12M-$-10.11M
Accumulated other comprehensive income (loss)-$-250K-$-410K-$-270K-$-200K$10K
Total equity$7.56M$15.5M$24.5M$34.6M$10.2M
Total investments$0.00$0.00$0.00$0.00$0.00
Total debt$11M$12M$5.96M$1.27M$3.62M
Net debt$10.6M$8.11M$4.08M-$-580K$1.87M
Cash flow statement
20252024202320222021
Net income-$-14.77M-$-14.86M-$-13.77M-$-14.01M-$-3.89M
Depreciation and amortization$4.78M$4.8M$4.85M$4.83M$2.04M
Stock-based compensation$1.73M$3.54M$1.11M$6.42M$150K
Change in working capital$730K$40K$190K-$-290K$440K
Accounts receivable$0.00$0.00$200K-$-200K$0.00
Inventory-$-150K$20K$220K-$-600K$0.00
Accounts payable$0.00$0.00$0.00$0.00$790K
Net cash provided by operating activities-$-4.61M-$-5.81M-$-4.69M-$-3.04M-$-1.25M
Investments in property, plant and equipment-$-30K-$-20K-$-90K-$-630K-$-140K
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities-$0.00-$-130K-$-100K-$-630K-$-180K
Common stock issued$2.01M$0.00$0.00$1.78M$0.00
Common stock repurchased-$0.00$0.00-$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$1.01M$8.03M$4.92M$3.85M$3.15M
Net change in cash-$-3.48M$2.01M$30K$100K$1.73M
Cash at end of period$420K$3.89M$1.89M$1.85M$1.75M
Operating cash flow-$-4.61M-$-5.81M-$-4.69M-$-3.04M-$-1.25M
Capital expenditure-$-30K-$-20K-$-90K-$-630K-$-140K
Free cash flow-$-4.65M-$-5.83M-$-4.79M-$-3.67M-$-1.39M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Ainos, Inc.

        Ainos, Inc. operates as a healthcare enterprise dedicated to advancing medical technologies. Its core focus involves developing both point-of-care diagnostic solutions and innovative, safe therapeutic options for various health conditions. The company's offerings include a COVID-19 antigen rapid test kit. This is complemented by the Ainos' cloud-based test management App, a holistic platform comprising the rapid test kit, a personal mobile application, and an enterprise-level app. Ainos also provides a COVID-19 nucleic acid test. Further technologies under development or offered include point-of-care testing for volatile organic compounds and Very Low-Dose Oral Interferon Alpha, an oral formulation of IFN-a with broad therapeutic potential. The firm is additionally developing a Synthetic RNA (SRNA) technology platform, with specific work being conducted in Taiwan. Beyond these, Ainos' product line extends to women's health, pneumonia, the Ainos Pen, AI Nose, and a variety of other products. Originally incorporated in 1984, the company was formerly known as Amarillo Biosciences, Inc. and rebranded to Ainos, Inc. in May 2021. Its main operations are based in San Diego, California.

        CEO
        Chun-Hsien Tsai
        Employees
        41
        Beta
        2.11

        Explore

        Frequently asked questions

        What is the intrinsic value of Ainos, Inc. (AIMDW)?

        InvestorsCraft does not currently publish an intrinsic value for AIMDW. How the IC value is calculated.

        Is AIMDW undervalued?

        InvestorsCraft does not publish an undervaluation signal for AIMDW at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.